查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1744565

2032 年細胞化驗分析市場預測：按產品類型、技術、應用、最終用戶和地區進行的全球分析

Cell Based Assays Market Forecasts to 2032 - Global Analysis By Product (Reagents, Assay Kits, Microplates, Probes & Labels and Other Products), Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球細胞化驗分析市場預計在 2025 年將達到 197 億美元，到 2032 年將達到 396 億美元，預測期內的複合年成長率為 10.5%。

細胞化驗分析是用來研究各種物質對活細胞影響的實驗技術。這些分析測量細胞反應，例如活力、增殖、細胞毒性、基因表現和訊號傳導，從而深入了解細胞功能和生物活性。細胞化驗分析常用於藥物研發、毒理學和生物醫學研究，與生化分析相比，它們能夠提供更生理相關性的模型，因為它們能夠解釋複雜的細胞過程和相互作用。細胞分析可用於多種細胞類型，包括原代細胞和細胞株，通常採用影像、發光、螢光或比色技術來量化反應。

根據美國心臟協會2022年1月發布的報告，美國每40秒就有一人被診斷出心肌梗塞。

對生技藥品和生物相似藥的需求不斷增加

對生技藥品和生物相似藥日益成長的需求是細胞化驗分析市場的主要驅動力。由於這些先進的療法需要嚴格的療效和安全性測試，細胞化驗分析能夠在藥物開發過程中提供準確且生理相關的洞見。這種日益成長的需求正在加速檢測技術的創新，從而提高通量和可靠性。製藥和生物技術公司越來越依賴這些檢測來簡化研究流程並滿足法規合規要求。因此，生技藥品產品線的擴展正在推動全球細胞化驗分析市場的持續成長和投資。

高成本

高昂的設備成本和持續的維護成本是細胞化驗分析市場成長的主要障礙。這些費用限制了其應用，尤其是在預算有限的小型實驗室和研究機構。經濟障礙限制了先進技術的獲取，減緩了研究進度，並降低了業務的擴充性。因此，新興市場，尤其是資金往往不足的市場，面臨市場擴張緩慢、創新受限和市場競爭力下降的問題。

技術進步

技術進步正在積極改變細胞化驗分析市場，提高檢測靈敏度、準確性和通量。自動化平台、高內涵篩檢和3D細胞培養系統等創新技術能夠加快藥物研發速度，並提高體外測試的預測性。人工智慧和機器學習的融合進一步簡化了數據分析，節省了時間和成本。這些進步支持精準醫療，增強了結果可信度，從而推動了製藥、生物技術和學術研究領域的顯著成長和應用。

複雜的法律規範

複雜的法律規範阻礙了細胞化驗分析市場的發展，導致產品認證延遲、合規成本增加以及開發商面臨不確定性。僵化且多樣化的全球法規阻礙了創新，並限制了市場准入，尤其對中小企業而言。這些挑戰阻礙了投資，並使新檢測的規模化發展變得複雜，最終限制了市場成長以及獲得先進細胞診斷和治療工具的管道。

COVID-19的影響

由於疫苗開發、藥物篩檢和診斷檢測需求的增加，COVID-19 疫情顯著加速了細胞化驗分析市場的成長。世界各地的實驗室將研究範圍擴大到抗病毒藥物和免疫反應領域，推動了先進檢測技術的採用。然而，早期的封鎖措施擾亂了供應鏈，並減緩了非疫苗研究的進展。整體而言，疫情促進了細胞化驗分析的技術創新和資金籌措，為疫情後市場持續成長奠定了基礎。

細胞活力檢測細分市場預計將成為預測期內最大的細分市場

預計細胞活力測定領域將在預測期內佔據最大的市場佔有率，因為它能夠精確測量活細胞，確保準確評估藥物療效和毒性，加速藥物發現和市場開發。該領域的需求不斷成長，主要源於其在癌症研究、再生醫學和個人化治療中的應用。測定技術的進步提高了靈敏度和通量，使細胞活力測定在生物醫學研究和製藥行業中至關重要，從而顯著促進了市場擴張。

藥物研發領域預計將在預測期內實現最高複合年成長率

由於對創新和精準檢測方法的需求，藥物研發領域預計將在預測期內實現最高成長率。由於製藥公司優先開發更安全、更有效的治療方法，細胞化驗分析能夠在研發早期階段提供有關藥物療效和毒性的關鍵資訊。這縮短了研發時間，降低了成本，並提高了成功率。因此，藥物研發領域的擴張正在推動細胞化驗分析的進步和應用，從而對市場擴張和創新產生積極影響。

佔比最大的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率。這是因為醫療基礎設施投資的不斷成長以及個人化醫療需求的不斷成長正在刺激技術創新。這些檢測方法可以實現更準確的藥物篩檢和毒性測試，從而改善患者預後並加速藥物研發。此外，中國、印度和日本等國日益增強的認知度和政府支持正在推動市場成長，促進經濟發展，並使該地區成為全球尖端生物技術研究中心。

複合年成長率最高的地區：

預計北美地區將在預測期內實現最高的複合年成長率，因為先進的檢測方法能夠準確分析細胞反應，改善疾病建模和毒性測試。這反過來又推動了生物技術和製藥領域的創新，從而提高了治療效果和患者預後。該地區強大的研發基礎設施和自動化技術的日益普及進一步推動了市場成長，創造了新的就業機會，並支持了醫療保健領域的進步。總體而言，北美在生命科學和醫療保健創新領域的領導地位正在加強。

免費客製化服務：

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章全球細胞化驗分析市場（按產品）

  • 試劑
  • 檢測試劑套件
  • 微孔盤
  • 探針和標籤
  • 設備和軟體
  • 細胞株
  • 其他產品

6. 全球細胞化驗分析市場（按類型）

  • 細胞活力測定
  • 細胞毒性試驗
  • 細胞死亡化驗
  • 細胞生長化驗
  • 其他類型

7. 全球細胞化驗分析市場（依技術）

  • 自動處理
  • 流式細胞技術
  • 高通量篩檢（HTS）
  • 無標定檢測
  • 其他技術

第8章全球細胞化驗分析市場（按應用）

  • 藥物研發
  • 基金會調查
  • ADME研究
  • 預測毒理學
  • 其他應用

第9章全球細胞化驗分析市場（按最終用戶分類）

  • 製藥和生物技術公司
  • 學術和政府研究機構
  • 受託研究機構（CRO）
  • 其他最終用戶

第10章全球細胞化驗分析市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Thermo Fisher Scientific
  • Danaher Corporation
  • Becton, Dickinson and Company（BD）
  • Merck KGaA
  • PerkinElmer Inc.
  • Bio-Rad Laboratories
  • Promega Corporation
  • Lonza Group AG
  • Agilent Technologies
  • Charles River Laboratories
  • Corning Incorporated
  • GE Healthcare
  • Sartorius AG
  • Eurofins Scientific
  • CytoSMART Technologies
  • Cell Signaling Technology
  • Miltenyi Biotec
  • Abcam plc
Product Code: SMRC29613

According to Stratistics MRC, the Global Cell Based Assays Market is accounted for $19.7 billion in 2025 and is expected to reach $39.6 billion by 2032 growing at a CAGR of 10.5% during the forecast period. Cell-based assays are experimental methods used to study the effects of various substances on living cells. These assays measure cellular responses such as viability, proliferation, cytotoxicity, gene expression, or signal transduction, providing insights into cellular function and biological activity. Commonly used in drug discovery, toxicology, and biomedical research, cell-based assays offer a more physiologically relevant model compared to biochemical assays, as they account for complex cellular processes and interactions. They can be performed using various cell types, including primary cells or cell lines, and often employ imaging, luminescence, fluorescence, or colorimetric techniques to quantify responses.

According to a report released by the American Heart Association in January 2022, every 40 seconds a person gets diagnosed with myocardial infarction in the U.S.

Market Dynamics:

Driver:

Rising demand for biologics and biosimilars

The rising demand for biologics and biosimilars is significantly propelling the cell-based assays market. As these advanced therapeutics require robust efficacy and safety testing, cell-based assays offer precise, physiologically relevant insights during drug development. This growing need accelerates innovation in assay technologies, enhancing throughput and reliability. Pharmaceutical and biotech companies increasingly rely on these assays to streamline research and regulatory compliance. Consequently, the expanding biologics pipeline directly drives sustained growth and investment in the global cell-based assays market.

Restraint:

High cost of instruments and maintenance

The high cost of instruments and ongoing maintenance significantly hinders the growth of the cell-based assays market. These expenses limit adoption, especially among smaller laboratories and research institutions with constrained budgets. Financial barriers restrict access to advanced technologies, slow research progress, and reduce the scalability of operations. Consequently, the market faces slower expansion, limited innovation, and reduced competitiveness, particularly in developing regions where funding is often inadequate.

Opportunity:

Technological Advancements

Technological advancements are positively transforming the cell-based assays market by enhancing assay sensitivity, accuracy, and throughput. Innovations such as automated platforms, high-content screening, and 3D cell culture systems enable faster drug discovery and more predictive in vitro testing. Integration of AI and machine learning further streamlines data analysis, reducing time and cost. These advancements support precision medicine and increase the reliability of results, driving significant growth and adoption across pharmaceutical, biotechnology, and academic research sectors.

Threat:

Complex regulatory frameworks

Complex regulatory frameworks hinder the Cell Based Assays market by causing delays in product approvals, increasing compliance costs, and creating uncertainty for developers. Stringent and varying global regulations slow innovation and limit market entry, especially for smaller companies. These challenges reduce investment incentives and complicate scaling of new assays, ultimately restricting market growth and accessibility of advanced cell-based diagnostic and therapeutic tools.

Covid-19 Impact

The Covid-19 pandemic significantly accelerated the growth of the cell-based assays market due to increased demand for vaccine development, drug screening, and diagnostic testing. Laboratories worldwide expanded research on antiviral drugs and immune responses, driving higher adoption of advanced assay technologies. However, initial lockdowns disrupted supply chains and delayed non-Covid research. Overall, the pandemic boosted innovation and funding in cell-based assays, positioning the market for sustained post-pandemic growth.

The cell viability assay segment is expected to be the largest during the forecast period

The cell viability assay segment is expected to account for the largest market share during the forecast period as it enabling precise measurement of living cells, it ensures accurate evaluation of drug efficacy and toxicity, accelerating drug discovery and development. This segment's rising demand is fueled by its application in cancer research, regenerative medicine, and personalized therapies. Advances in assay technologies enhance sensitivity and throughput, making cell viability assays indispensable for biomedical research and pharmaceutical industries, thereby significantly boosting market expansion.

The drug discovery segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the drug discovery segment is predicted to witness the highest growth rate, due to demand for innovative and precise testing methods. As pharmaceutical companies prioritize developing safer, more effective therapies, cell-based assays offer critical insights into drug efficacy and toxicity early in the pipeline. This accelerates R&D timelines, reduces costs, and improves success rates. Consequently, the expanding drug discovery sector propels advancements and adoption of cell-based assays, positively impacting market expansion and technological innovation.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to growing investments in healthcare infrastructure and rising demand for personalized medicine are fueling innovation. These assays enable more accurate drug screening and toxicity testing, improving patient outcomes and accelerating drug discovery. Additionally, increasing awareness and government support in countries like China, India, and Japan are boosting market growth, fostering economic development, and positioning the region as a global hub for cutting-edge biotechnological research.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, as advanced assays enable precise analysis of cellular responses, improving disease modeling and toxicity testing. This fosters innovation in biotechnology and pharmaceuticals, enhancing treatment effectiveness and patient outcomes. The region's strong R&D infrastructure and growing adoption of automated technologies further boost market growth, creating new job opportunities and supporting healthcare advancements. Overall, it strengthens North America's leadership in life sciences and healthcare innovation.

Key players in the market

Some of the key players profiled in the Cell Based Assays Market include Thermo Fisher Scientific, Danaher Corporation, Becton, Dickinson and Company (BD), Merck KGaA, PerkinElmer Inc., Bio-Rad Laboratories, Promega Corporation, Lonza Group AG, Agilent Technologies, Charles River Laboratories, Corning Incorporated, GE Healthcare, Sartorius AG, Eurofins Scientific, CytoSMART Technologies, Cell Signaling Technology, Miltenyi Biotec and Abcam plc.

Key Developments:

In April 2025, GE HealthCare and FPT Corporation have expanded their strategic partnership to accelerate AI-driven healthcare innovation. This collaboration includes the establishment of an FPT Competency Center in Vietnam, aimed at enhancing product strategy, development, and customer onboarding within GE HealthCare's digital ecosystem.

In March 2025, NVIDIA and GE HealthCare have announced a collaboration to advance autonomous diagnostic imaging, focusing on developing AI-driven X-ray and ultrasound technologies. This partnership aims to address the global shortage of radiology professionals and improve access to medical imaging services.

In January 2025, Sutter Health and GE HealthCare have entered into a seven-year strategic partnership, known as the "Care Alliance," aimed at enhancing diagnostic imaging services across California.

Products Covered:

  • Reagents
  • Assay Kits
  • Microplates
  • Probes & Labels
  • Instruments & Software
  • Cell Lines
  • Other Products

Types Covered:

  • Cell Viability Assay
  • Cytotoxicity Assay
  • Cell Death Assay
  • Cell Proliferation Assay
  • Other Types

Technologies Covered:

  • Automated Handling
  • Flow Cytometry
  • High-Throughput Screening (HTS)
  • Label-Free Detection
  • Other Technologies

Applications Covered:

  • Drug Discovery
  • Basic Research
  • ADME Studies
  • Predictive Toxicology
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Government Research Institutes
  • Contract Research Organizations (CROs)
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cell Based Assays Market, By Product

  • 5.1 Introduction
  • 5.2 Reagents
  • 5.3 Assay Kits
  • 5.4 Microplates
  • 5.5 Probes & Labels
  • 5.6 Instruments & Software
  • 5.7 Cell Lines
  • 5.8 Other Products

6 Global Cell Based Assays Market, By Type

  • 6.1 Introduction
  • 6.2 Cell Viability Assay
  • 6.3 Cytotoxicity Assay
  • 6.4 Cell Death Assay
  • 6.5 Cell Proliferation Assay
  • 6.6 Other Types

7 Global Cell Based Assays Market, By Technology

  • 7.1 Introduction
  • 7.2 Automated Handling
  • 7.3 Flow Cytometry
  • 7.4 High-Throughput Screening (HTS)
  • 7.5 Label-Free Detection
  • 7.6 Other Technologies

8 Global Cell Based Assays Market, By Application

  • 8.1 Introduction
  • 8.2 Drug Discovery
  • 8.3 Basic Research
  • 8.4 ADME Studies
  • 8.5 Predictive Toxicology
  • 8.6 Other Applications

9 Global Cell Based Assays Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical & Biotechnology Companies
  • 9.3 Academic & Government Research Institutes
  • 9.4 Contract Research Organizations (CROs)
  • 9.5 Other End Users

10 Global Cell Based Assays Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific
  • 12.2 Danaher Corporation
  • 12.3 Becton, Dickinson and Company (BD)
  • 12.4 Merck KGaA
  • 12.5 PerkinElmer Inc.
  • 12.6 Bio-Rad Laboratories
  • 12.7 Promega Corporation
  • 12.8 Lonza Group AG
  • 12.9 Agilent Technologies
  • 12.10 Charles River Laboratories
  • 12.11 Corning Incorporated
  • 12.12 GE Healthcare
  • 12.13 Sartorius AG
  • 12.14 Eurofins Scientific
  • 12.15 CytoSMART Technologies
  • 12.16 Cell Signaling Technology
  • 12.17 Miltenyi Biotec
  • 12.18 Abcam plc

List of Tables

  • Table 1 Global Cell Based Assays Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Cell Based Assays Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Cell Based Assays Market Outlook, By Reagents (2024-2032) ($MN)
  • Table 4 Global Cell Based Assays Market Outlook, By Assay Kits (2024-2032) ($MN)
  • Table 5 Global Cell Based Assays Market Outlook, By Microplates (2024-2032) ($MN)
  • Table 6 Global Cell Based Assays Market Outlook, By Probes & Labels (2024-2032) ($MN)
  • Table 7 Global Cell Based Assays Market Outlook, By Instruments & Software (2024-2032) ($MN)
  • Table 8 Global Cell Based Assays Market Outlook, By Cell Lines (2024-2032) ($MN)
  • Table 9 Global Cell Based Assays Market Outlook, By Other Products (2024-2032) ($MN)
  • Table 10 Global Cell Based Assays Market Outlook, By Type (2024-2032) ($MN)
  • Table 11 Global Cell Based Assays Market Outlook, By Cell Viability Assay (2024-2032) ($MN)
  • Table 12 Global Cell Based Assays Market Outlook, By Cytotoxicity Assay (2024-2032) ($MN)
  • Table 13 Global Cell Based Assays Market Outlook, By Cell Death Assay (2024-2032) ($MN)
  • Table 14 Global Cell Based Assays Market Outlook, By Cell Proliferation Assay (2024-2032) ($MN)
  • Table 15 Global Cell Based Assays Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 16 Global Cell Based Assays Market Outlook, By Technology (2024-2032) ($MN)
  • Table 17 Global Cell Based Assays Market Outlook, By Automated Handling (2024-2032) ($MN)
  • Table 18 Global Cell Based Assays Market Outlook, By Flow Cytometry (2024-2032) ($MN)
  • Table 19 Global Cell Based Assays Market Outlook, By High-Throughput Screening (HTS) (2024-2032) ($MN)
  • Table 20 Global Cell Based Assays Market Outlook, By Label-Free Detection (2024-2032) ($MN)
  • Table 21 Global Cell Based Assays Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 22 Global Cell Based Assays Market Outlook, By Application (2024-2032) ($MN)
  • Table 23 Global Cell Based Assays Market Outlook, By Drug Discovery (2024-2032) ($MN)
  • Table 24 Global Cell Based Assays Market Outlook, By Basic Research (2024-2032) ($MN)
  • Table 25 Global Cell Based Assays Market Outlook, By ADME Studies (2024-2032) ($MN)
  • Table 26 Global Cell Based Assays Market Outlook, By Predictive Toxicology (2024-2032) ($MN)
  • Table 27 Global Cell Based Assays Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 28 Global Cell Based Assays Market Outlook, By End User (2024-2032) ($MN)
  • Table 29 Global Cell Based Assays Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 30 Global Cell Based Assays Market Outlook, By Academic & Government Research Institutes (2024-2032) ($MN)
  • Table 31 Global Cell Based Assays Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)
  • Table 32 Global Cell Based Assays Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.